Omeros Corporation Prepays $67.1 Million Senior Secured Term Loan, Terminates Credit Agreement
Omeros Corporation has prepaid its $67.1 million senior secured term loan, including all associated costs, leading to the termination of the credit agreement and release of related liens and covenants. The company plans to use proceeds from a recent asset sale to repay its 2026 Convertible Notes and fund operations for over 12 months, including the U.S. launch of narsoplimab.
Omeros Corporation has prepaid the entire $67.1 million principal amount outstanding under its senior secured term loan, including a pre-payment premium, accrued and unpaid interest, and related expenses. This prepayment has resulted in the termination of the senior secured credit agreement and the release of all associated liens and covenants, such as the $25.0 million minimum liquidity covenant. The company expects that remaining proceeds from its recent asset sale will be sufficient to repay the outstanding $17.1 million principal balance on its 2026 Convertible Notes and fund over 12 months of operations, including the anticipated U.S. launch of narsoplimab for transplant-associated thrombotic microangiopathy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-036507), on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
